Pharma

#Digital therapeutics #Pharma

Sidekick Health raises $55m to expand DTx portfolio   

Digital therapy company Sidekick Health has raised $55 million in Series B funding to help it expand its business. The round was led by London-based venture capital firm Novator Ventures, with additional participation from Wellington Partners, Asabys Partners, and Frumtak Ventures, as well as a US-based strategic investor. … Read More

#News

#Autoimmune disease #Immunology #Pharma

Understanding and innovating in immunology

Listen to this article on the DDW Podcast: Chiedzo Mpofu, Vice President, Global Medical Affairs Head, Immunology, at AbbVie, talks to Lu Rahman about our understanding of auto-immune disease and how AbbVie is continuing to innovate in this field. “Immune mediated diseases are a diverse group of conditions that… Read More

#Exclusive Content

#Acquisition #Business #Immuno-oncology #Pharma

GSK to acquire Sierra Oncology in £1.5bn deal 

GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced.   Sierra Oncology  Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being… Read More

#Business & Investment #News

#Alzheimer's #Clinical trials #Pharma

Winterlight Labs launches speech assessment collaboration  

Digital biomarkers developer Winterlight Labs and memory clinic Alzheimer Center Amsterdam will work together on a project to decentralise assessments of patients’ cognition and function in the study of preclinical Alzheimer’s disease.   The project will see Alzheimer Center Amsterdam develop a remote measurement toolbox, integrating Winterlight’s digital… Read More

#News

#Drug development #Drug discovery #Pharma

Target product profiles and strategies for drug development

Hettie Stroebel, Founder and CEO of Launch Excellence looks at how target product profiles can be used by life sciences companies as a strategy for more effective product development.    The global effort to develop and distribute a SARS-CoV-2 vaccine in months is a triumph for the pharmaceutical industry. It is… Read More

#News #Opinion

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported… Read More

#News #Trending News #Trends & Analysis

#Biotechnology #Pharma #Pharmacovigilance #Regulatory

Listicle: Experts on the differences between FDA and EMA regulations

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US… Read More

#Listicles #News #Sponsored Content #Videos

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Biomarkers #Clinical trials #Covid-19 #Pharma #Pneumonia #Research

Ruconest-treated patients test lower disease severity scores for Covid-19 

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven. … Read More

#News

#Biotherapeutics #Collaboration #Funding #HIV #Pharma

This week in drug discovery (16-20 August) 

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University … Read More

#News #Trending News

#Pharma #Pharmaceuticals #Therapeutics

Digital brain biomarker start-up appoints Acacia founder to board 

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments. Read More

#Business & Investment #News #Start-up Zone

#Immuno-oncology #Oncology #Pharma #Tumour biology

BridgeBio collaborates with Bristol Myers Squibb

BridgeBio Pharma has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO (nivolumab) in patients with advanced solid tumours with KRAS mutations with the hope of providing an effective new treatment option for patients with difficult-to-treat cancers.  The… Read More

#Cancer Research #News

#Biotechnology #Pharma #Pharmacovigilance #Regulatory

FDA vs EMA: biotechs & the challenges of international pharmacovigilance

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant in Paris and Judi Sills in New Jersey highlight the main differences between US and EU requirements, and advise on best preparations. Small biotech companies are commanding… Read More

#Editor's Choice #Exclusive Content #News #Regulatory

#Biomedicine #Collaboration #Life sciences #Pharma

Stop, collaborate and listen: podcast

This is the latest episode of the free DDW podcast, “Stop, collaborate and listen: a model for successful pharma and vendor engagement”. It covers a narrated article written for DDW and read aloud by Megan Thomas. Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities… Read More

#Editor's Choice #News